Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · KREBS BIOCHEMICALS & IND · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
KREBS BIOCHEMICALS & IND
NSE: KREBSBIO · BSE: 524518
NSE: KREBSBIO · BSE: 524518
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
KREBS BIOCHEMICALS & IND
StateQ1 FY27 filed
Last close · 21 Sept 2026₹59.50
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA— · — · —
KREBS BIOCHEMICALS & IND is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 53 | 52 | 50 | 43 | 24 |
| EBITDA (ex other income) | (41) | (16) | (9) | (15) | (5) |
| margin % | (77.0) | (30.3) | (17.3) | (34.7) | (23.0) |
| Owners' profit | (45) | (25) | (20) | (27) | (17) |
| EPS, as reported (₹) | (20.81) | (11.30) | (9.16) | (12.49) | (7.85) |
| ROE % · ROCE % | 59.3 · (35.0) | 24.8 · (17.3) | 16.5 · (12.9) | 18.4 · (32.1) | 10.4 · (19.6) |
| Debt / equity (x) | (1.90) | (1.84) | (1.62) | (1.45) | (1.38) |
| Cash from operations | (17) | (26) | 2 | (8) | (2) |
| Capex | (27) | (11) | (8) | (5) | (4) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KREBS BIOCHEMICALS & IND · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 11 | 6 | 5 | 4 | 7 | 7 | 7 |
| Profit before tax | (6) | (8) | (8) | (5) | (6) | (3) | (2) | (2) |
| Net profit | (6) | (8) | (8) | (5) | (6) | (3) | (2) | (2) |
| EPS (₹) | (2.67) | (3.59) | (3.83) | (2.47) | (2.85) | (1.45) | (1.09) | (1.15) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| ROCE | (33.7) | 10.8 | 173 of 183 | 6% |
| ROE | 10.4 | 10.4 | 86 of 171 | 50% |
| Debt / Equity | (1.4) | 0.1 | 3 of 171 | 99% |
| EBITDA margin | 14.1 | 17.5 | 95 of 165 | 43% |
| Revenue growth | 27.4 | 16.3 | 53 of 161 | 68% |
| Profit growth | 53.3 | 30.9 | 64 of 158 | 60% |
| Market cap | 121 | 770 | 129 of 184 | 30% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · KREBS BIOCHEMICALS & IND · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 21 Sept 2026 · Trading window closed for Q2 FY27 results at Krebs Biochemicals | compliance | minimal | — | — |
| 7 Sept 2026 · Newspaper notice published for 34th AGM on 29 September 2026 | compliance | minimal | — | — |
| 4 Sept 2026 · 34th AGM on Sep 29, 2026; seeks nod for Rs 120 Cr Ipca Labs related party deals | board shareholder meetings | medium | — | — |
| 4 Sept 2026 · Annual Report FY26 filed; AGM set for 29 September 2026 | results | high | — | — |
| 3 Sept 2026 · Notice of 34th AGM on 29 September 2026 via video conferencing | compliance | minimal | — | — |
| 7 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 6 Aug 2026 · Q1 FY27 results: revenue up 27 percent, loss narrows to Rs 2.48 cr | results | high | — | — |
| 28 Jul 2026 · Board Meeting on Aug 6 2026 to Consider Q1 FY27 Results | board shareholder meetings | low | — | — |
| 2 Jul 2026 · Reg 74(5) Depository Certificate for Q1 FY27 filed with exchanges | compliance | minimal | — | — |
| 2 Jul 2026 · RTA cert filed under SEBI Reg 74(5) for Jun 2026 quarter | compliance | minimal | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in